Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis

摘要

Langerhans cell histiocytosis (LCH), a rare neoplasm predominantly affecting young children, is characterized by accumulation of abundant CD1a+ CD207+ histiocytes with inflammatory lesions.1 Recurrent BRAF V600E mutations have been identified in approximately 50% of LCH patients, which are correlated with high-risk features of LCH and increased resistance to the first-line therapy.2,3 Several recent studies have indicated cell-free (cf) BRAF V600E analysis in plasma can serve as a promising biomarker in LCH.4,5 However, the prognostic significance of cfBRAF V600E during chemotherapy remains to be proven. In this study, we monitored cfBRAF V600E at different time points during chemotherapy in children with LCH, and evaluated the correlation of the dynamics of cfBRAF V600E with patients' clinical outcomes.